Press Release
November 2, 2023

Goodwin Represents the Initial Purchasers and Dealers on Amphastar Pharmaceuticals, Inc.’s $345 million 2.00% Convertible Senior Notes Offering

The Capital Markets team advised the initial purchasers on Amphastar Pharmaceuticals, Inc.’s Rule 144A offering of 2.00% Convertible Senior Notes due 2029. The initial conversion price of the notes represents a premium of approximately 35% to the last reported sale price of Amphastar’s common stock on the pricing date (the “reference price”).

Based in Rancho Cucamonga, California, Amphastar (Nasdaq: AMPH) is a bio-pharmaceutical company focusing primarily on developing, manufacturing, marketing and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient products.

Goodwin’s product team consisted of Jim Barri, John Servidio, Kim de Glossop and Sne Sadhu. The corporate and securities team consisted of Ben Marsh, Sne Sadhu and Rylee Sherouse. The regulatory and specialist teams consisted of Alexander Varond, Sarah Wicks and Matt Wetzel and Heath Ingram (Healthcare Regulatory); Olivia Uitto (IP); Jackie Klosek (Privacy); and Dan Karelitz and Nicole Brock (Tax).

For more information, please see Amphastar’s pricing press release for the offering.